Long‐term efficacy and safety of deprenyl (selegiline) in advanced Parkinson's disease
- 1 August 1989
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 39 (8) , 1109
- https://doi.org/10.1212/wnl.39.8.1109
Abstract
Twenty-two patients with advanced Parkinson''s disease whose symtom fluctuations had initially responded to deprenyl supplementation were followed for 19 to 27 months on that drug. The improvement disappeared in most cases after a mean of 7-8 months but persists at latest follow-up in 5 patients. Transient or continuing abnormalities in liver function tests occurred in 9 patients.This publication has 0 references indexed in Scilit: